Core Viewpoint - The article emphasizes the importance of continuous technological innovation and stable industrial systems in the global medical technology industry, highlighting the launch of the "Global MedTech Awards" by Siyu MedTech to recognize companies that positively impact the industry through innovation, collaboration, and long-term investment [2]. Group 1: Award Criteria - The awards focus on companies' capabilities in technology and product innovation, assessing their ability to convert innovations into stable product systems that provide clinical value [3]. - The evaluation also considers the role of companies in industrial collaboration and ecosystem building, including their efforts in resource integration and enhancing industry efficiency through capital, technology, or organizational capabilities [4]. - Companies are assessed on their sustainable development and long-term investment strategies, particularly in R&D, manufacturing, localization, and social responsibility in key markets like China [5]. Group 2: Award Winners - Medtronic, a leading global medical technology company, received the "Medical Technology Industry Contribution Award" for its long-term commitment to cardiovascular, neurostimulation, and chronic disease management, showcasing significant contributions in technology innovation and industry collaboration [9][10]. - Stryker, recognized for its advancements in orthopedic and minimally invasive technologies, was awarded for its systematic investments in technology and ecosystem development, particularly in surgical robotics and pain management [13][14]. - Boston Scientific was acknowledged for its leadership in cardiovascular and neurostimulation fields, with notable innovations like the FARAPULSE™ system for atrial fibrillation treatment and a focus on enhancing clinical capabilities through strategic acquisitions [17][18]. - Alcon, a prominent player in the ophthalmic sector, was awarded for its continuous innovation in eye care technologies, including the Voyager™ DSLT system and advancements in cataract and refractive surgery [22][23]. - MicroPort, recognized for its multi-platform capabilities in high-end medical devices, demonstrated significant progress in product maturity and international market expansion, earning the award for its systematic approach to technology and clinical application [25][27]. - United Imaging Healthcare, a representative of high-end medical imaging equipment in China, was awarded for its technological innovations and global expansion efforts, particularly in ultrasound and AI applications [31][32].

最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《董事、高级管理人员薪酬管理制度》 《关于召开2026年第一次临时股东会的通知》 截至2025年12月31日收盘，可孚医疗（301087）报收于44.67元，较前一交易日上涨1.34%，最新总市值 为93.31亿元。该股当日开盘44.15元，最高44.71元，最低43.88元，成交额达7457.31万元，换手率为 0.87%。 近日，可孚医疗科技股份有限公司发布《董事、高级管理人员薪酬管理制度》公告。公告显示，公司已 制定董事、高级管理人员薪酬管理制度，明确薪酬管理原则、机构职责、薪酬标准、发放管理、薪酬调 整及其他激励事项。根据制度内容，独立董事领取津贴，非独立董事按实际岗位领取薪酬，高级管理人 员薪酬由基本年薪和绩效奖金构成。薪酬与考核委员会负责制定考核标准和薪酬方案，董事会和股东会 分别审议高管和董事薪酬。存在违规行为的，将不予发放年终奖励或追回已发薪酬。 ...

Core Insights - In 2025, the market capitalization increment of A-share listed companies in Guangdong Province reached 42.7 billion, representing a growth of 27.95% compared to the beginning of the year [1] Group 1: Market Capitalization Growth - The top five companies contributing to market capitalization growth all exceeded 100 billion, with Industrial Fulian leading at an increment of 805 billion, marking a growth rate of 188.46% and contributing 18.85% to the total market capitalization increase in the province [1] - The remaining four companies in the top five, namely China Ping An, Shenghong Technology, Luxshare Precision, and Shunyi Technology, each had market capitalization increments below 300 billion, with their contributions to the overall growth rate not exceeding 7% [1] Group 2: Market Capitalization Decline - The companies experiencing the most significant market capitalization decline in Guangdong Province included Mindray Medical, Haitian Flavoring, Huali Group, Poly Development, and Transsion Holdings [1] - Mindray Medical's market capitalization decreased by 78.3 billion, which is significantly higher than the other four companies, each of which saw declines not exceeding 40 billion [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688656 | 浩欧博 | 153.80 | -8.03% | 2.07万 | 3.29 乙 | | 301122 | 采纳股份 | 26.06 | -3.80% | 1.61万 | 4256.87万 | | 301363 | 美好医疗 | 24.05 | -3.80% | 7.34万 | 1.78亿 | | 688767 | 博拓生物 | 37.78 | -3.08% | 1 2.31万 | 8813.10万 | | 300760 | 迈瑞医疗 | 190.45 | -2.63% | 11.37万 | 21.82亿 | | 600807 | 济高发展 | 3.08 | -2.53% | 36.60万 | 1.13亿 | | 920278 | 鹿得医疗 | 8.91 | -2.41% | 4.04万 | 3626.05万 | | 688805 | 健信超导 | 42.14 | -2.23% | 5.73万 | 2.42 乙 | | 603205 ...

Core Viewpoint - Mindray Medical is facing temporary pressure in the domestic market due to multiple factors, but sees a historic opportunity for import substitution in the IVD market, aiming to double its market share in the next three years in the fields of chemiluminescence, biochemistry, and coagulation [1][3][4]. Market and Business Outlook - The domestic market has experienced a decline in capacity over the past two years, but the company believes this impact is temporary. The demand for quality improvement and cost control in medical institutions presents a significant opportunity for high-end breakthroughs and import substitution [3][4]. - The company expects positive growth in domestic business by 2026, with IVD leading the growth of three major product lines and emerging businesses achieving rapid growth [4]. Emerging Business Segments - Mindray's emerging businesses, including minimally invasive surgery, minimally invasive intervention, and animal healthcare, are projected to reach nearly 3.9 billion RMB in 2024, contributing over 10% to total revenue, and exceed 2.6 billion RMB in the first half of 2025, contributing over 15% [2][14]. - The minimally invasive surgery market is expected to grow significantly, with a projected market size of approximately 37.3 billion RMB in China by 2024, and a growth rate of 10.8% from 2024 to 2030 [15]. - The minimally invasive intervention market is also rapidly expanding, with a projected market size of approximately 32.5 billion RMB in China by 2024, driven by factors such as aging population and increasing prevalence of cardiovascular diseases [16]. Technological and Competitive Advantages - Mindray has established significant core advantages in the ultrasound market through nearly 30 years of investment, including a comprehensive product line, deep clinical insights, and a global platform [2][6][7]. - The company is leveraging AI technology and clinical expertise to create intelligent solutions that enhance operational efficiency and improve patient care [7][8]. Integration and Collaboration - The integration with Huatai Medical is progressing as planned, with a focus on enhancing operational efficiency and management standards while respecting the independence of Huatai [10][11]. - Mindray aims to deepen collaboration across various functions to strengthen Huatai's competitiveness in the cardiovascular field [11]. AI and Digital Solutions - Mindray's AI models have been successfully implemented in top hospitals, enhancing digital transformation and supporting precision medicine [12][13]. - The company is committed to integrating AI solutions with hardware and IT systems to maximize the effectiveness of its digital healthcare offerings [13].

Group 1 - The company has not yet produced any medical robot-related products as of the current date [2]

Core Viewpoint - Antu Biology (603658.SH) has received the "High-tech Enterprise Certificate" for its wholly-owned subsidiary Zhengzhou Yimeno Biotechnology Co., Ltd. and its secondary subsidiary Zhengzhou Biaoyuan Biotechnology Co., Ltd. This recognition allows the subsidiaries to benefit from tax incentives for three years from 2025 to 2027 [1] Group 1 - The subsidiaries were re-certified as high-tech enterprises after the expiration of their previous certificates [1] - The certificate numbers are GR202541002114 and GR202541001628, with an issuance date of November 4, 2025, and a validity period of three years [1] - The subsidiaries will enjoy a corporate income tax rate of 15% as part of the national tax incentives for high-tech enterprises [1]

每经AI快讯，可孚医疗12月31日晚间发布公告称，公司第二届第二十次董事会会议于2025年12月31日 在公司六楼会议室召开。会议审议了《关于召开2026年第一次临时股东会的议案》等文件。 每日经济新闻 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——2025十大财经新闻出炉！护航、酣战、变局、狂飙分别指向哪些大事件？ ...

来源：新浪证券-红岸工作室 12月31日，春立医疗跌0.31%，成交额2447.40万元，换手率0.37%，总市值87.76亿元。 异动分析 医疗器械概念+智能医疗+牙科医疗+专精特新+京津冀一体化 1、公司是国内领先的骨科医疗器械厂商，主营业务系植入性骨科医疗器械的研发、生产与销售。公司 主要产品为关节假体产品及脊柱类植入产品，其中关节假体产品涵盖髋、膝、肩、肘四大人体关节，脊 柱类植入产品为脊柱内固定系统的全系列产品组合。 5、公司位于北京市通州区通州经济开发区南区鑫觅西二路10号。公司是国内领先的骨科医疗器械厂 商，主营业务系植入性骨科医疗器械的研发、生产与销售。公司主要产品为关节假体产品及脊柱类植入 产品，其中关节假体产品涵盖髋、膝、肩、肘四大人体关节，脊柱类植入产品为脊柱内固定系统的全系 列产品组合。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-329.32万，占比0.13%，行业排名91/133，连续3日被主力资金减仓；所属行业主力净流 入-9.43亿，连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-329. ...

华兰股份(301093.SZ)公告称，公司董事会同意在董事会战略与投资委员会下设AI医药专家委员会，由3 名委员组成，其中主任委员1名。委员会将为公司AI医药相关业务提供全局性战略规划与技术指导，构 建产学研协同创新生态，并链接世界顶尖专家资源和国际客户资源。此外，公司选举LIU JUN（刘军） 先生、孙茂松先生、赵宏先生担任AI医药专家委员会委员，其中LIU JUN（刘军）先生担任主任委员。 ...